Karthikeyan Ranganathan, MD
Interventional Cardiology · Pittsburgh, PANPI 1013358605
Payments from drug & device makers
Across 189 payments — averaging $62.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$2K
- Abiomed$1K
- Philips North America LLC$739
- Johnson & Johnson$704
- AstraZeneca$643
- plus $4K from 28 others
What the payments were for
- Consulting fees$5935%
- Travel & lodging$2742%
- Food & beverage$10,56189%
- Education$3123%
- Gifts$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $2,451 |
| Medtronic(2 entities) | 34 | $1,955 |
| Abiomed | 18 | $1,377 |
| Philips North America LLC | 3 | $739 |
| Johnson & Johnson | 15 | $704 |
| AstraZeneca | 11 | $643 |
| Inari Medical, Inc. | 5 | $416 |
| Boston Scientific | 10 | $402 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $390 |
| Shockwave Medical, Inc | 2 | $223 |
| Getinge USA Sales, LLC | 4 | $211 |
| Boehringer Ingelheim | 2 | $200 |
| Edwards Lifesciences | 1 | $182 |
| Endotronix, Inc. | 1 | $181 |
| E.r. Squibb & Sons, L.L.C. | 5 | $176 |
| Cook Medical LLC | 2 | $163 |
| Cerus Corporation | 3 | $137 |
| Angiodynamics, Inc. | 1 | $132 |
| W. L. Gore & Associates, Inc. | 1 | $125 |
| La Jolla Pharmaceutical Company | 1 | $123 |
| Vifor Pharma, Inc. | 1 | $117 |
| Penumbra, Inc. | 1 | $117 |
| Bayer | 1 | $109 |
| Amgen | 4 | $101 |
| Cardiovascular Systems Inc. | 4 | $88 |
| Chiesi USA, Inc. | 1 | $75 |
| Cardiva Medical, Inc. | 1 | $73 |
| Novartis | 3 | $71 |
| Livanova USA, Inc. | 1 | $27 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Mindray DS USA, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $22 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$779
- Impella$665
- (1439) HPM Undiv$593
- CoreValve Evolut$538
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$372
- XARELTO$355
- FARXIGA$331
- HeartMate 3 Left Ventricular Dev$312
- COREVALVE EVOLUT R$286
- BRILINTA$231
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$223
- FLOWTRIEVER CATHETER, S$202
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$182
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$181
- Cook Medical Zilver PTX$160
- COROFLOW$153
- AngioVac$132
- CardioMEMS HF System$129
- GORE CARDIOFORM Septal Occluder$125
- GIAPREZA$123
How this compares
$11,816 in reported general payments places this provider in the 55th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 11 | $155,213 |
| EntrestoSacubitril/Valsartan | 176 | $143,122 |
| EliquisApixaban | 96 | $81,971 |
| JardianceEmpagliflozin | 72 | $47,095 |
| XareltoRivaroxaban | 62 | $46,094 |
| FarxigaDapagliflozin Propanediol | 24 | $17,698 |
| BrilintaTicagrelor | 12 | $7,108 |
| Ranolazine ErRanolazine | 30 | $2,669 |
| Bumetanide | 49 | $2,118 |
| Metoprolol Succinate | 135 | $2,036 |
| Valsartan | 45 | $1,311 |
| Spironolactone | 225 | $1,141 |
| Atorvastatin Calcium | 81 | $1,058 |
| Potassium Chloride | 30 | $971 |
| Carvedilol | 115 | $746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $109 | $155,21311 claims |
| NovartisEntresto | $71 | $143,122176 claims |
| PfizerEliquis | $14 | $81,97196 claims |
| Boehringer IngelheimJardiance | $200 | $47,09572 claims |
| Johnson & JohnsonXarelto | $704 | $46,09462 claims |
| AstraZenecaFarxiga, Brilinta | $643 | $24,80636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Pittsburgh
- Ramzi KhalilPittsburgh$1.6M
- David LasordaPittsburgh$1.1M
- Catalin TomaPittsburgh$522K
- Anson SmithPittsburgh$518K
- Saad TabbaraPittsburgh$355K
- Suresh MulukutlaPittsburgh$260K
- Ryan ZuzekPittsburgh$152K
- Dustin KlinerPittsburgh$93K
- Mithun ChakravarthyPittsburgh$79K
- William GrayWynnewood$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.